論文 - 詳細
| RRC ID | 42979 |
|---|---|
| 著者 | Maehara H, Kaname T, Yanagi K, Hanzawa H, Owan I, Kinjou T, Kadomatsu K, Ikematsu S, Iwamasa T, Kanaya F, Naritomi K. |
| タイトル | Midkine as a novel target for antibody therapy in osteosarcoma. |
| ジャーナル | Biochem Biophys Res Commun |
| Abstract |
Osteosarcoma is a malignant tumor with poor prognosis, and lack of accurate prognostic factors is one of the reasons that make this tumor difficult to cure. The heparin-binding growth factor, midkine is involved in generation and progression of many types of tumors. However, the relationship between midkine and osteosarcoma has been unclear. We show here that midkine is overexpressed in osteosarcoma and the level of midkine expression is correlated with prognosis (P<0.05; log-rank test). Treatment with functional antibodies against midkine suppresses growth of osteosarcoma cell lines, 9N2, 3N1, Saos-2, and NOS-1, to 25-65% of untreated controls. Our results suggest that midkine is useful as a prognostic marker, and is a candidate therapeutic target for osetosarcomas. |
| 巻・号 | 358(3) |
| ページ | 757-62 |
| 公開日 | 2007-7-6 |
| DOI | 10.1016/j.bbrc.2007.04.183 |
| PII | S0006-291X(07)00914-X |
| PMID | 17506984 |
| MeSH | Adolescent Adult Antibodies / chemistry* Bone Neoplasms / therapy* Cell Line, Tumor Cell Proliferation Child Cytokines / chemistry* Cytokines / pharmacology* Gene Expression Regulation, Neoplastic* Humans Immunohistochemistry Immunotherapy / methods* Midkine Osteosarcoma / therapy* Prognosis Retrospective Studies |
| IF | 2.985 |
| 引用数 | 23 |
| WOS 分野 | BIOPHYSICS BIOCHEMISTRY & MOLECULAR BIOLOGY |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | Patent(IFI CLAIMS) |
| 各媒体での言及数の合計 | 10 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| ヒト・動物細胞 | NOS-1(RCB1032) |